Nieves Hornbeck, MD
Family Medicine · Hartford, CTNPI 1780635771
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 473 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,350 and has fallen 57.6% since, to $1,846 in 2025. Among family medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 473 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$951
- Novo Nordisk$584
- Bayer$569
- Lilly USA, LLC$519
- Sumitomo Pharma America, Inc.$433
- plus $5K from 34 others
What the payments were for
- Food & beverage$9,18798%
- Education$1452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $1,110 |
| AstraZeneca | 37 | $951 |
| Novo Nordisk | 24 | $584 |
| Bayer | 33 | $569 |
| Lilly USA, LLC | 24 | $519 |
| Sumitomo Pharma America, Inc. | 29 | $433 |
| Otsuka America Pharmaceutical, Inc. | 23 | $430 |
| Astellas Pharma US Inc | 22 | $338 |
| Amgen | 8 | $286 |
| Vanda Pharmaceuticals Inc. | 9 | $268 |
| Axsome Therapeutics, Inc. | 7 | $267 |
| Novartis | 13 | $256 |
| Boehringer Ingelheim | 7 | $247 |
| Ardelyx, Inc. | 11 | $240 |
| Mylan Specialty L.p. | 16 | $226 |
| Phathom Pharmaceuticals, Inc. | 15 | $216 |
| Merck | 9 | $201 |
| Teva Pharmaceuticals USA, Inc. | 9 | $195 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $182 |
| Viatris Specialty LLC | 14 | $177 |
| Exact Sciences | 8 | $175 |
| UCB, Inc. | 5 | $162 |
| Pfizer | 8 | $140 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $139 |
| Lundbeck LLC | 6 | $133 |
| Johnson & Johnson | 6 | $129 |
| SK Life Science, Inc. | 4 | $105 |
| Corcept Therapeutics | 5 | $96 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Abbott | 4 | $86 |
| Alkermes, Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| GSK | 3 | $65 |
| Dexcom, Inc. | 3 | $61 |
| Endo Pharmaceuticals Inc. | 2 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Inari Medical, Inc. | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Indivior Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,332 in reported general payments places this provider in the 90th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 107 | $134,061 |
| LinzessLinaclotide | 84 | $105,972 |
| FarxigaDapagliflozin Propanediol | 71 | $96,636 |
| MounjaroTirzepatide | 53 | $81,294 |
| TrulicityDulaglutide | 37 | $69,588 |
| OzempicSemaglutide | 40 | $68,288 |
| JanuviaSitagliptin Phosphate | 37 | $55,057 |
| RybelsusSemaglutide | 21 | $53,755 |
| VraylarCariprazine Hcl | 27 | $40,878 |
| GemtesaVibegron | 33 | $36,521 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $31,570 |
| RexultiBrexpiprazole | 21 | $31,158 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $27,270 |
| EliquisApixaban | 24 | $25,985 |
| TrulancePlecanatide | 16 | $25,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $519 | $150,88290 claims |
| AbbVieLinzess, Vraylar | $1,110 | $146,850111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma, Symbicort | $951 | $145,445142 claims |
| Boehringer IngelheimJardiance | $247 | $134,061107 claims |
| Novo NordiskOzempic, Rybelsus | $584 | $122,04461 claims |
| MerckJanuvia, Janumet, Janumet Xr, Belsomra | $201 | $111,04991 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $433 | $36,52133 claims |
| PfizerEliquis, Premarin | $140 | $36,42047 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $430 | $31,15821 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $182 | $25,95316 claims |
| GSKBreo Ellipta, Incruse Ellipta | $65 | $20,54935 claims |
| Astellas Pharma US IncMyrbetriq | $338 | $19,32414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Hartford
- Mohammad Samer YounesHartford$20K
- Mouhanad AyachHartford$8K
- Mark BelskyHartford$8K
- Charlecinth RobertsHartford$8K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.